Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intellia Therapeutics Inc.

www.intelliatx.com

Latest From Intellia Therapeutics Inc.

If PTAB Backs Berkeley IP Holders' New Patent Claims, CRISPR Licensing Could Be Simplified

The USPTO's PTAB will determine whether UC-Berkeley or Broad Institute holders of CRISPR patents first invented its use in eukaryotic cells. The outcome could either benefit the Berkeley group, which could simplify licensing deals, or maintain the status quo.

Intellectual Property Business Strategies

Genexine Hopes To Become 'Asia’s Amgen' After ToolGen Merger

With an ambition to become an Amgen-like global biopharma, South Korea's Genexine decides to merge with local genome editing firm ToolGen to progress potential global blockbusters such as universal CAR-T therapies.

South Korea M & A

ERS Genomics Completes 45 CRISPR Licensing Deals To Date, Largely For Screening, Discovery

Despite being ineligible to license its CRISPR technology for human gene and cell therapy applications, ERS is doing considerable business with biopharmas for internal R&D projects.

Deals Intellectual Property

The Case For CAR-T Grows As Responses Hold Up Longer Term

Novartis and Gilead longer-term data show largely steady response and survival rates, shoring up the clinical and commercial case for their products and justifying continued investment in T-cell therapies. The CAR-T pioneers discuss their progress, including with allogeneic platforms, with Scrip at ASH.

ImmunoOncology Research and Development Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Gene Therapy, Cell Therapy
    • Large Molecule
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Intellia Therapeutics Inc.
  • Senior Management
  • John Leonard, MD, Pres. & CEO
    Graeme Bell, EVP, CFO
    Jennifer King, PhD, SVP, Bus. Dev.
    Laura Sepp-Lorenzino, PhD, CSO
  • Contact Info
  • Intellia Therapeutics Inc.
    Phone: (857) 285-6200
    40 Erie St.
    Cambridge, MA 02139
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register